The following are due in March (this is per page 21 of the Entitlement Offer Document -see announcement of 16 Jan):
- Results of study on DX1 in combination with PARPi (brain cancer animal data)
- Initiation of stable cell line development
The latest announcement said that results of glioblastoma (brain cancer requiring crossing of BBB) on live mice will be announced this month - this refer to the same test noted in the first point above.
The major accumulator could drive the SP if it a pharma wanting a partenering deal.
Also the expectation of these announcements could drive the SP up.
There generally a leaky boat, so any daily SP rises could be a good indicator.
The latest announcement noted that the brain tumor shrunk by 40%. If the next results are great we could cross 10 cents within a day. Well crossing a few cents is not a big ask if we cross the BBB in live mice. I believe this will happen anytime now. Then a re-rate and if confidence grows, a $200 million market cap is not out of question.
Disclosure: I hold millions of shares.
Brainy
Note: Prima Biomed went to a market cap of a few years ago $366 million on hype only.
Add to My Watchlist
What is My Watchlist?
